TOPLINE: A recent analysis found that neoadjuvant chemoimmunotherapy led to higher 2-year overall survival and disease-free survival (DFS) rates than neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Chemoimmunotherapy was also associated with lower overall recurrence and distant metastasis rates but a similar locoregional metastasis rate compared with chemoradiotherapy. METHODOLOGY: While […]
The post Chemoimmunotherapy Vs Standard Care in ESCC: Is One Better? first appeared on News Health.
Author : News Health
Publish date : 2025-03-26 06:24:00
Copyright for syndicated content belongs to the linked Source.